ArticlePLoS neglected tropical diseases2018
Quantification of dengue virus specific T cell responses and correlation with viral load and clinical disease severity in acute dengue infection.
Article in PLoS neglected tropical diseases, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 45 citations in OpenAlex.
- Association of dengue virus-specific polyfunctional T-cell responses with clinical disease severity in acute dengue infection.Immunity, inflammation and disease · 2019Trial
- Acute-Phase Dengue Antibody Profiles in Pediatric Patients: Influence on Viremia and Disease Manifestations.Viruses · 2026Article
- Targeting dengue through mucosal vaccination: the potential of NS1 and bacterial spore-based delivery platforms.Frontiers in immunology · 2026Review
- T Cell Responses During Dengue Infection.Current topics in microbiology and immunology · 2026Review
- Development and Immunogenicity Assessment of a Multi-Epitope Antigen Against Zika Virus: An In Silico and In Vivo Approach.Vaccines · 2025Article
- Transcriptome Analysis of Monocytes Treated With Dengue Virus Nonstructural Protein 1 Revealed a Shift in Transcripts Involved in Self-Propagated Proinflammation and Antiviral Responses.The Journal of infectious diseases · 2025Article
- Functionality and phenotype of T cells in patients with varying severity of acute dengue and metabolic status.medRxiv : the preprint server for health sciences · 2025Article
- Review
- Secondary Dengue Infection Elicits Earlier Elevations in IL-6 and IL-10 Levels.International journal of molecular sciences · 2024Article
- The Flavivirus Non-Structural Protein 5 (NS5): Structure, Functions, and Targeting for Development of Vaccines and Therapeutics.Vaccines · 2024Review
- Dengue.Lancet (London, England) · 2024Review
- Democratizing Pathological Image Segmentation with Lay Annotators via Molecular-empowered Learning.Medical image computing and computer-assisted intervention : MICCAI ... International Conference on Medical Image Computing and Computer-Assisted Intervention · 2023Article
- Phase 1 trial to model primary, secondary, and tertiary dengue using a monovalent vaccine.BMC infectious diseases · 2023Article
- Association of viral kinetics, infection history, NS1 protein with plasma leakage among Indonesian dengue infected patients.PloS one · 2023Article
- Development of Inapparent Dengue Associated With Increased Antibody Levels to Aedes aegypti Salivary Proteins: A Longitudinal Dengue Cohort in Cambodia.The Journal of infectious diseases · 2022Article
- Dengue virus co-opts innate type 2 pathways to escape early control of viral replication.Communications biology · 2022Article
- Dengue and COVID-19: two sides of the same coin.Journal of biomedical science · 2022Review
- Transcriptomics of Acute DENV-Specific CD8+ T Cells Does Not Support Qualitative Differences as Drivers of Disease Severity.Vaccines · 2022Article
- Pathogenesis and virulence of flavivirus infections.Virulence · 2021Review
- Changing epidemiology of dengue in Sri Lanka-Challenges for the future.PLoS neglected tropical diseases · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 2 countries.
Funding
Abstract
backgroundIn order to understand the role of dengue virus (DENV) specific T cell responses that associate with protection, we studied their frequency and phenotype in relation to clinical disease severity and resolution of viraemia in a large cohort of patients with varying severity of acute dengue infection. METHODOLOGY/PRINCIPAL
findingsUsing ex vivo IFNγ ELISpot assays we determined the frequency of dengue viral peptide (DENV)-NS3, NS1 and NS5 responsive T cells in 74 adult patients with acute dengue infection and examined the association of responsive T cell frequency with the extent of viraemia and clinical disease severity. We found that total DENV-specific and DENV-NS3-specific T cell responses, were higher in patients with dengue fever (DF), when compared to those with dengue haemorrhagic fever (DHF). In addition, those with DF had significantly higher (p = 0.02) DENV-specific T cell responses on day 4 of infection compared to those who subsequently developed DHF. DENV peptide specific T cell responses inversely correlated with the degree of viraemia, which was most significant for DENV-NS3 specific T cell responses (Spearman's r = -0.47, p = 0.0003). The frequency of T cell responses to NS1, NS5 and pooled DENV peptides, correlated with the degree of thrombocytopenia but had no association with levels of liver transaminases. In contrast, total DENV-IgG inversely correlated with the degree of thrombocytopenia and levels of liver transaminases. CONCLUSIONS/SIGNIFICANCE: Early appearance of DENV-specific T cell IFNγ responses before the onset of plasma leakage, appears to associate with milder clinical disease and resolution of viraemia, suggesting a protective role in acute dengue infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.